Daily Ards Research Analysis
Analyzed 17 papers and selected 3 impactful papers.
Summary
Analyzed 17 papers and selected 3 impactful articles.
Selected Articles
1. Detection of drug-induced acute respiratory distress syndrome risk signals in FAERS: a real-world pharmacovigilance study.
Using FAERS, the authors detected disproportionate ARDS reporting signals across multiple drug classes and identified 22 specific drugs associated with increased ARDS risk. ARDS typically occurred within 150 days of treatment initiation (median 30 days), with higher representation in middle-aged/older adults and slightly more in males.
Impact: This is the largest real-world pharmacovigilance assessment to date focused on drug-induced ARDS, providing a prioritized list of high-risk medications and temporal onset patterns.
Clinical Implications: Clinicians should heighten surveillance for ARDS when initiating high-risk drugs (e.g., immunosuppressants, antineoplastics, amiodarone), particularly during the first 1–5 months, and consider differential diagnosis of drug-induced ARDS when new hypoxemia and bilateral infiltrates emerge.
Key Findings
- 15,986 ARDS-related adverse event reports identified in FAERS with male predominance and concentration in middle-aged/older adults
- Top reported drugs: mycophenolic acid, methotrexate, rituximab, tacrolimus, and amiodarone
- Strong disproportionality signals for prednisone, mycophenolic acid, amiodarone, and cytarabine
- Multivariable analysis identified 22 drugs significantly associated with ARDS risk
- Median time to ARDS onset was 30 days; ~75% occurred within 150 days of treatment start
Methodological Strengths
- Use of multiple disproportionality methods combined with LASSO and multivariable regression for robustness
- Large-scale dataset with standardized MedDRA coding and deduplication
Limitations
- Spontaneous reporting biases and underreporting limit causal inference
- Lack of detailed clinical covariates (e.g., ARDS Berlin criteria, ventilatory data) and exposure denominators
Future Directions: Prospective pharmacoepidemiologic studies with validated ARDS phenotyping and exposure denominators to quantify absolute risks; signal substantiation via EHR-based cohorts and mechanistic studies for implicated drugs.
BACKGROUND: Drug-induced acute respiratory distress syndrome (ARDS) represents an often overlooked yet potentially severe adverse reaction in clinical practice. Existing evidence predominantly stems from isolated case reports, and systematic investigations based on large-scale real-world data remain limited. This study aimed to comprehensively evaluate the risk signals of drug-related ARDS and identify potential high-risk drug classes using the US FDA Adverse Event Reporting System (FAERS). METHODS: We retrieved data from FAERS and extracted ARDS-related reports based on the MedDRA Preferred Terms (PT), followed by deduplication and data cleaning. Four disproportionality analysis methods were used to detect drug signals. LASSO regression and multivariable logistic regression were applied to identify potential independent risk factors. The time interval from drug exposure to ARDS onset was also assessed. RESULTS: A total of 15,986 drug-related ARDS reports were included, with the highest proportion occurring in middle-aged and older adults, and slightly more cases in males than in females. The five most frequently reported drugs were mycophenolic acid, methotrexate, rituximab, tacrolimus, and amiodarone. Signal detection indicated strong associations for prednisone, mycophenolic acid, amiodarone, and cytarabine. Multivariable analyses further identified 22 drugs significantly associated with ARDS risk. The median time to ARDS onset was 30 days, and approximately 75% of cases occurred within 150 days after treatment initiation. CONCLUSION: Using real-world data, this study identified multiple drug classes with significantly elevated ARDS risk, including immunosuppressants, antineoplastic agents, glucocorticoids, cardiovascular drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs). These findings provide important evidence for clinical monitoring of high-risk medications.
2. Beyond immunomodulation: mechanisms and synergistic strategies of mesenchymal stem cells in promoting alveolar epithelial and endothelial repair in ARDS.
This mechanistic review synthesizes how MSCs promote alveolar epithelial and endothelial repair in ARDS via paracrine factors, extracellular vesicles, mitochondrial transfer, and modulation of apoptosis and barrier function. It outlines synergistic strategies (e.g., preconditioning, gene editing, biomaterial scaffolds) and highlights translational barriers including timing, heterogeneity, and safety.
Impact: It reframes MSCs in ARDS beyond immunomodulation toward direct epithelial/endothelial repair, providing a mechanistic roadmap for combinatorial, precision approaches.
Clinical Implications: While not yet practice-changing, the synthesis supports designing phenotype- and timing-specific trials of MSCs (or MSC-derived products) targeting barrier repair in ARDS.
Key Findings
- MSCs promote alveolar epithelial and endothelial repair via paracrine signaling, extracellular vesicles, and mitochondrial transfer
- Repair mechanisms include modulation of apoptosis, tight junctions, cytoskeletal dynamics, and glycocalyx integrity
- Synergistic strategies include preconditioning, gene editing, pharmacologic augmentation, and biomaterial scaffolds
- Translational challenges include patient heterogeneity, disease stage, dosing/timing, manufacturing, and safety monitoring
Methodological Strengths
- Comprehensive synthesis of multi-level mechanisms linking MSC actions to epithelial/endothelial repair
- Integration of bioengineering and gene-editing advances to propose testable synergistic strategies
Limitations
- Narrative review without PRISMA methodology or quantitative synthesis
- Translational claims rely on preclinical data with limited human trial validation
Future Directions: Stratified early-phase trials aligning MSC products with ARDS biological phenotypes and repair timing; standardized potency assays and manufacturing; head-to-head testing of MSC-derived extracellular vesicles vs cells.
ARDS is a life-threatening lung disease marked by severe AECS and ECs damage, causing rapid lung function loss and high mortality. MSCs are promising therapies due to their immunoregulatory and regenerative properties. While early studies highlighted MSCs' anti-inflammatory effects in ARDS, recent findings emphasize their essential role in repairing the AECs and ECs. In this review, we detail the molecular mechanisms and synergistic effects of MSCs in epithelial and endothelial repair. We also examine how MSC-mediated immune regulation intersects with tissue repair, explore new combination approaches using drugs, gene editing, and bioengineering, and outline clinical limitations and ongoing challenges. Patient heterogeneity, disease stage, treatment timing, and safety issues limit the conduct of clinical trials and their translation. We summarize the roles, limitations, and challenges of MSCs in ARDS to guide future research and inform the development of new treatments.
3. ECMO for patients with obesity: evidence and practice.
This review concludes that obesity should not be a contraindication for VV-ECMO, with outcomes comparable to non-obese patients in retrospective data, while underscoring optimized conventional ARDS management before ECMO. It details obesity-related technical considerations for cannulation, anticoagulation, and perfusion, and highlights heterogeneity in VA-ECMO outcomes, especially in ECPR.
Impact: Provides pragmatic guidance for a rapidly growing ARDS subgroup—patients with obesity—potentially reducing inappropriate exclusion from VV-ECMO and improving peri-ECMO management.
Clinical Implications: Do not exclude VV-ECMO solely due to obesity; exhaust optimized ARDS bundles (lung-protective ventilation, prone positioning) first, then apply individualized cannulation and anticoagulation strategies with adequate infrastructure and multidisciplinary protocols.
Key Findings
- Obesity is not a contraindication to VV-ECMO; outcomes are comparable or possibly better than in non-obese patients in retrospective studies
- Optimize conventional ARDS management (ventilatory strategies, prone positioning) before ECMO due to obesity-related respiratory mechanics
- VA-ECMO outcomes are heterogeneous, particularly in ECPR, and depend on selection, comorbidities, and timing
- Obesity introduces technical challenges necessitating tailored cannulation, anticoagulation, and perfusion strategies
Methodological Strengths
- Consolidation of multi-domain evidence (epidemiology, physiology, outcomes, and technical management)
- Clear, practice-oriented recommendations for patient selection and peri-ECMO strategies
Limitations
- Predominantly retrospective evidence with BMI-based classifications; limited prospective data
- Narrative synthesis without systematic review methodology or meta-analysis
Future Directions: Prospective, obesity-specific ECMO registries and trials to refine selection thresholds, anticoagulation targets, and cannulation strategies; evaluation of long-term outcomes and rehabilitation.
PURPOSE: Obesity is increasingly encountered among patients requiring extracorporeal membrane oxygenation (ECMO) for severe respiratory or cardiac failure. It alters respiratory and cardiovascular physiology and drug pharmacokinetics and introduces technical and logistical challenges that may complicate patient selection, ECMO initiation, cannulation, anticoagulation, and monitoring. This review summarizes current evidence regarding the epidemiology, physiological implications, outcomes, and management of obesity in patients supported with veno-venous (VV) or veno-arterial (VA) ECMO. RESULTS: Available evidence, largely retrospective and based on body mass index classifications, suggests that obesity should not be considered a contraindication to VV-ECMO, with outcomes comparable to or potentially better than those of patients without obesity. However, obesity-related respiratory mechanics may exaggerate the apparent severity of lung injury, emphasizing the need for optimized conventional ARDS management, including appropriate ventilatory strategies and prone positioning, before ECMO initiation. In contrast, outcomes during VA-ECMO are more heterogeneous, particularly in extracorporeal cardiopulmonary resuscitation (ECPR), and may be influenced by patient selection, comorbidities, and timing of support. Obesity also creates important technical challenges requiring individualized cannulation, anticoagulation, and perfusion strategies. CONCLUSION: Obesity alone should not preclude access to ECMO, particularly VV-ECMO. Successful management requires anticipation of obesity-related challenges, appropriate infrastructure, and structured multidisciplinary protocols. Further prospective studies are needed to clarify obesity-specific risks, optimize management strategies, and evaluate long-term outcomes.